Actuate Therapeutics, Inc. Common stock

Day range

$0.33 – $0.39

Open

$0.38

Prev close

$0.37

Volume

489.47K

Market cap

$8.05M

Shares out

24.01M

P/E

—

P/S

—

P/B

8.25

P/FCF

—

ROE

-2067.8%

ROA

-393.4%

Debt/Equity

0.04

Div yield

0.00%

As of Oct 30, 2026

• Listing deficiency noticeOct 30, 2026

  On October 28, 2026, Actuate Therapeutics, Inc. received a written notice from The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1).

• Public offeringOct 28, 2026

  The combined public offering price for each set of two shares of common stock and one accompanying Common Warrant to purchase one share of common stock is $0.71, before underwriting discounts and commissions. On October 28, 2026, the Company closed the Offering.

• Listing deficiency noticeJul 17, 2026

  On July 15, 2026, Actuate Therapeutics, Inc. received a letter from the listing qualifications department staff of The Nasdaq Stock Market notifying the Company that from June 1, 2026 to July 14, 2026, the Company's Market Value of Listed Securities (MVLS) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from the date of the Notice, or through January 11, 2027, to regain compliance with respect to the MVLS Requirement.

• Annual meeting resultsMay 22, 2026

  At the Annual Meeting, the Company's stockholders (i) elected each of the two Class II director nominees listed below to the Company's Board of Directors, each to serve for a three-year term until the 2029 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified; and (ii) ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Regulatory decisionMay 11, 2026

  On May 11, 2026, Actuate Therapeutics, Inc. (the "Company") issued a press release announcing FDA clearance of an Investigational New Drug ("IND") application to conduct a Phase 1/2 study and future plans to advance the elraglusib development program.

Days to cover

4.7

Short interest

1.87M

Avg volume

396.89K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
  neutralGlobeNewswire Inc.· Oct 27, 2026
• AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
  positiveZacks Investment Research· Oct 8, 2026
• Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
  positiveGlobeNewswire Inc.· Jun 1, 2026
• Actuate Therapeutics to Present at The Citizens Life Sciences Conference
  positiveGlobeNewswire Inc.· Mar 4, 2026
• Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
  neutralBenzinga· Sep 11, 2025